First Wave BioPharma Inc logo

First Wave BioPharma Inc

$ 1.84 +0.19 (+11.52%) 04:00 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 2.55M
Enterprise V:
$ 1.60M
Volume:
1.43M
Avg Vol (2M):
1.18M
Also Trade In:
Volume:
1.43M
Market Cap $:
2.55M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.18M
Enterprise Value $:
1.60M
PB Ratio:
0
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
First Wave BioPharma Inc is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
Name Current Vs Industry Vs History
Cash-To-Debt 2.44
Equity-to-Asset -3.61
Debt-to-Equity -0.03
Debt-to-EBITDA -0.01
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 7.7
3-Year EPS without NRI Growth Rate -2.5
3-Year FCF Growth Rate 12.6
Name Current Vs Industry Vs History
5-Day RSI 56.03
9-Day RSI 38.96
14-Day RSI 34.72
6-1 Month Momentum % -89.18
12-1 Month Momentum % -96.19

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.1
Quick Ratio 0.1
Cash Ratio 0.07

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -103.2
Name Current Vs Industry Vs History
ROA % -557.79
ROIC % -1006.71
ROC (Joel Greenblatt) % -13670.53

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -0.03
EV-to-EBITDA -0.03
EV-to-Forward-Revenue -64.47
EV-to-FCF -0.05
Earnings Yield (Greenblatt) % -3019.09

Financials (Next Earnings Date:2022-11-15 Est.)

FWBI's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:FWBI

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -120.3
Beta 1.85
Volatility % 53.7
14-Day RSI 34.72
14-Day ATR ($) 0.380073
20-Day SMA ($) 1.9675
12-1 Month Momentum % -96.19
52-Week Range ($) 1.19 - 106.5
Shares Outstanding (Mil) 1.39

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

First Wave BioPharma Inc Filings

Document Form Filing Date
No Filing Data

First Wave BioPharma Inc Analysis

Share your research

Headlines

See More
No news.